Discover Great Companies Discover Great Clients
Popularity  2万   |   Followers  8   |   Likes  5   |   Feedback  2 Claim this company

Application of single-cell analysis technology

No.419 Pukou District Popularity Ranking Nanjing Jiangsu No.14 Fen Zi Sheng Wu Xue No.26 Jian Kang Sheng Huo No.36 Reagents No.42 Inspection No.46 Healthcare Healthy No.55 Intellectual Property No.55 Health Technology No.57 Testing No.63 Yu Fang Bao Jian No.69 Health Care No.73 Health Services No.76 Rehabilitation Management 高新技术企业 科技型中小企业 省级高新技术企业 省科技型中小企业 发明专利 软件著作权
More

Company Overview

  • Nature: Joint Venture Size: 500-999 employees Founded: 8年
  • Industry: Testing and Certification 、 Enterprise Services 、 Pharmaceuticals/Bioengineering 、 Beauty/Wellness
  • Full name: Singleron (Nanjing) Biotechnology Co., Ltd.。

Development Stage

  • Stage: B轮 , 金额未透露。
  • Honors: 高新技术企业 科技型中小企业 According to algorithm
  • Salary: 94.7% of positions earn 8-15K, In 2026 vs last yeargrew by 16%.。Master's salary: ¥12.1K.
  • R&D: "Scientific Research" demand: 56.1%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 7%, "Mechanical/Instrumentation": 3.5%。
  • Recruiting: In 2026 vs 2025decreased by 2%. Demand for highly educated talent: Master's: 4.
  • Requirement: Education: 本科 leads with 61.4%. Experience: 1-3年 leads with 59.6%.
  • Region: Distributed across 5 regions, 南京: 17.5%, 北京: 10.5%, 成都: 10.5%, 上海: 8.8%.

About the Company

[Summary] Application of single-cell analysis technology

Singleron Biotechnologies is dedicated to applying breakthrough single-cell technologies to the fields of scientific research, clinical testing, health management, and drug development. Singleron Biotechnologies is dedicated to applying breakthrough single-cell technologies to the fields of scientific research, clinical testing, health management, and drug development. The company was registered and established in January 2018. In May 2018, it secured a tens-of-millions-of-yuan angel round led by Oriza Seed. In June 2019, it obtained a nearly-100-million-yuan Pre-A round led by Sherpa Healthcare Partners. In September, November, and December 2020, it successively completed Series A, A1, and A2 rounds totaling approximately US$70 million. In November 2021, it secured a nearly-US$100-million Series B round led by CBC Group. To date, Singleron has raised nearly US$200 million in total. It has laboratories and offices in Nanjing, Suzhou, Germany, the United States, and Singapore, and has served more than 4,000 research institutions, hospitals, and pharmaceutical companies in nearly 20 countries worldwide. After its establishment, the company quickly attracted a group of high-level entrepreneurial talents, and multiple individuals were selected into talent introduction programs such as "Entrepreneurship Jiangbei," "Entrepreneurship Nanjing," "Suzhou Industrial Park Major*," "Gusu*," and "Jiangsu Province Dual-Innovation Talent." Core team members have worked for many years in genetic testing, microfluidic system R&D, single-cell amplification and library construction reagent product development, bioinformatics analysis and database construction, instrument design and development, and clinical testing product development, possessing mature and profound experience in technological innovation and product development as well as rich and successful commercialization outcomes. The company signed a licensing agreement with Yale University for microfluidic single-cell processing patents, and using this patent together with its proprietary single-cell amplification technology, developed the innovative GEXSCOPE® single-cell technology platform based on microfluidic chips, breaking through the bottlenecks of conventional single-cell sequencing technology in terms of turnaround time, throughput, and cost, and removing obstacles for the application of single-cell analysis technology in clinical testing. The company is committed to independently developing innovative technologies and has obtained 94 patents in areas such as instrument and microfluidic system design, single-cell amplification and library construction methods and workflows, and data analysis algorithms, as well as 87 software copyrights. In January 2019, it launched single-cell transcriptome sequencing products, including a complete solution of microfluidic chips, reagents, and bioinformatics analysis software. In 2020, it launched Singleron Matrix®, an automated single-cell sequencing preprocessing instrument. Currently, the company has established strategic cooperation with multiple universities and hospitals at home and abroad to jointly promote the clinical application of single-cell technology. At the same time, in the fierce competition of the "China Innovation & Entrepreneurship Competition" hosted by the Ministry of Science and Technology, the company stood out from more than 10,000 participating enterprises and won the Excellence Award in the National Biomedicine Finals for two consecutive years in 2018 and 2019, fully representing industry experts' and the market's recognition of the company's team, core technologies, and business model. As a breakthrough new technology, single-cell analysis technology is expected to gradually replace traditional bulk-sample next-generation sequencing. Currently, the global potential scientific research market has reached more than US$13 billion, and the segmented market for single-cell sequencing technology is growing year by year at an average annual rate of more than 20%. The application prospects of single-cell analysis technology in clinical and drug development are even broader; it can replace or supplement existing technologies for molecular, cellular, and tissue pathology testing, and can also be used for emerging cell therapies. Singleron upholds the innovative philosophy of "investigating things to attain knowledge, discerning the微小 to understand the origin" and is committed to developing simple and reliable massive single-cell omics technologies, making them a new-generation means of cellular and molecular pathology and blood testing, and enabling single-cell omics to serve fields such as precision medicine and health management with high accuracy, high sensitivity, and high resolution.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Singleron Biotechnologies Financing History (4 rounds)

Manage
B轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 金额未透露
  • Investor: 清池资本,晨壹投资,和玉资...

Singleron Biotechnologies How Fast Is Hiring Growing? (3 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Down 41%
  • 2024: Down 16%
  • 2023: Up 12%
  • 2022: Down 48%
Singleron Biotechnologies Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Singleron Biotechnologies Campus Recruitment & Advanced Degree Talent Demand
Master's 4
Note: How fast is hiring at Singleron (Nanjing) Biotechnology Co., Ltd. growing? Singleron Biotechnologies2026: 54 openings (down 2%), 2025: 55 openings (down 41%), 2024: 93 openings (down 16%), 2023: 111 openings (up 12%), 2022: 99 openings (down 48%), 2021: 191 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Singleron Biotechnologies Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Down 39%
  • 2024: Down 28%
  • 2023: Down 18%
  • 2022: Up 129%
Singleron Biotechnologies Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Singleron (Nanjing) Biotechnology Co., Ltd. growing? Singleron BiotechnologiesMaster's recruitment over the years: 2025: 14 openings (down 39%), 2024: 23 openings (down 28%), 2023: 32 openings (down 18%), 2022: 39 openings (up 129%), 2021: 17 openings.

Singleron Biotechnologies Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Singleron Biotechnologies Doctoral Hiring by Year: 2023 — 18 fewer jobs than 2022
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Singleron (Nanjing) Biotechnology Co., Ltd. growing? Singleron BiotechnologiesDoctorate recruitment over the years: 2023: 5 openings (down 18%), 2022: 23 openings (up 129%), 2021: 5 openings.

Singleron Biotechnologies R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Singleron (Nanjing) Biotechnology Co., Ltd.? Based on an analysis of Singleron Biotechnologies's job postings over the past year, "Scientific Research" demand: 56.1%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 7%, "Mechanical/Instrumentation": 3.5%, "Other (R&D and Technical)": 1.8%, "Electronics/Electrical/Communication Technology": 1.8%, "Computer/Network/Technology": 1.8%. For reference only.

Singleron Biotechnologies — What Are the Salaries Like? (57 records)

Manage
Singleron Biotechnologies Salary Overview
salary range: 6K - 50K, 94.7% of roles pay ¥8-15K
Note: salary statistics are based on 57 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Singleron (Nanjing) Biotechnology Co., Ltd.?Singleron Biotechnologies94.7% of positions earn 8-15K, Undergraduate salary: ¥。Nanjing salary ranking top 50,Sales average salary ¥12.0K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Singleron Biotechnologies

(More)
Are salaries high at Singleron (Nanjing) Biotechnology Co., Ltd.? We provide: Sales, Technical Consultant, 省区经理, Operations, Business Development, Embedded Engineer, Technical Support, New Media Specialist. Click to view detailed salary analysis by job.

Singleron Biotechnologies honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • Sales
    91.2% of total 91.2%
  • Scientific Research
    56.1% of total 56.1%
  • Biology/Pharmaceutical/Chemical/Environmental Protection
    7% of total 7%
  • Customer Service
    3.5% of total 3.5%

Education

  • 本科
    61.4% of total 61.4%
  • 硕士
    31.6% of total 31.6%
  • 不限
    7% of total 7%

Experience

  • 1-3年
    59.6% of total 59.6%
  • 不限
    35.1% of total 35.1%
  • 3-5年
    5.3% of total 5.3%
View Detailed Analysis

What does Singleron (Nanjing) Biotechnology Co., Ltd. require? Who is Singleron Biotechnologies hiring? Singleron Biotechnologies recruitment: Sales占比最多占91.2%,其次是Scientific Research占56.1%. What education can get in at Singleron Biotechnologies? 本科占比最多占61.4%,其次是硕士占31.6%. High education required at Singleron Biotechnologies? 硕士占31.6%. Work experience required at Singleron Biotechnologies? 1-3年占比最多占59.6%,其次是不限占35.1%. Where are the job locations at Singleron Biotechnologies? 南京占比最多占17.5%,其次是北京占10.5%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 35,000万(元)
Legal Representative: FANG NAN
Date Established:
Credit Code: 91320100MA1UY8MP8X
Registered Address: 南京市江北新区华康路142号南京生物医药谷加速器三期A01栋北侧四层

People who follow Singleron Biotechnologies also follow

Singleron Biotechnologies Competitors (Similar Companies)

诊断试剂 试剂 分子诊断试剂 体外诊断仪器
“日出实业集团有限公司是一家集生产、研发、国际贸易为一体的综合性化工集团企业。”
“婴儿保育设备专业制造商”
风险管理 信贷 金融 资产管理
传感器 温度传感器 热电偶 生产
螺钉 螺丝 劳保用品 液压机床
“Mainly develops immersion liquid systems for high-end lithography mach”
石墨 石墨制品 分子筛 密封件
功能食品 生产 化妆品 日化/日用化工
抽水蓄能 发电设备 水利 电力设备
“为中国文具享誉世界而孜孜以求”
生产 材料科技 永磁材料 钕铁硼
薄膜电容器 薄膜 电子元件 生产
铝管 发动机 液压成形 先进制造
“Manufacturer of communication electronics and communication physical c”

Discover Great Companies, Discover Great Clients

南京公司名录 南京“Pukou District”公司名录 南京“生物科技/生物工程”公司名录 南京“医药”公司名录 南京“生物医药”公司名录 南京“试剂”公司名录 南京“药物研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates